Hexarelin: Research Profile

Palmetto Peptides Research Team

February 22, 2026

growth-hormonehexarelinpeptidesresearch

Hexarelin (examorelin, EP-23905) is a synthetic hexapeptide growth hormone secretagogue (GHS) — His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2 — developed as a research analog of GHRP-6 with substantially enhanced potency at the growth hormone secretagogue receptor (GHSR-1a). Hexarelin is among the most potent GHRPs described in the literature, producing GH pulse amplitudes that exceed those of GHRP-2, GHRP-6, and Ipamorelin at comparable doses. However, its research profile extends beyond pituitary GH-releasing activity — hexarelin demonstrates unique cardiovascular effects through the CD36 receptor, a scavenger receptor expressed on cardiomyocytes and macrophages, establishing it as a multi-target research compound.

Structure and Potency

Hexarelin's structure incorporates D-2-methyltryptophan (D-2-MeTrp) at position 2 — a key modification that confers superior GHSR-1a binding affinity compared to D-Trp used in GHRP-6. The hexapeptide sequence provides an optimal balance of receptor binding geometry, metabolic stability, and pharmacokinetic properties. Comparative studies have established hexarelin's GH-releasing potency ranking: hexarelin > GHRP-2 > GHRP-6 > ipamorelin at equivalent molar doses in animal models, though the selectivity profiles diverge significantly.

Mechanism of Action

GHSR-1a Agonism

Like all GHRPs, hexarelin activates GHSR-1a — the Gq/11-coupled G protein-coupled receptor on pituitary somatotrophs — triggering intracellular calcium mobilization and GH vesicle exocytosis. Hexarelin's higher binding affinity for GHSR-1a versus GHRP-6 results in greater GH pulse amplitude, but also more rapid receptor desensitization (tachyphylaxis) with repeated dosing — a key research limitation that distinguishes hexarelin from compounds like ipamorelin that show more sustained responsiveness with chronic administration protocols.

CD36 Receptor Activity: Cardiovascular Research

The most distinctive feature of hexarelin's research profile — absent in ipamorelin and most other GHRPs — is its high-affinity binding to CD36 (fatty acid translocase), a multifunctional scavenger receptor expressed abundantly on cardiomyocytes, macrophages, platelets, and adipocytes. This CD36 binding is independent of GHSR-1a and produces several cardiovascular effects that have generated substantial research interest:

Cardioprotection in ischemia-reperfusion models: Hexarelin pretreatment in animal myocardial infarction models significantly reduced infarct size, preserved left ventricular function, and attenuated cardiomyocyte apoptosis. These effects were observed in GH-deficient animals and after GHSR-1a blockade — confirming CD36-mediated, GH-independent cardioprotection.
Cardiac function in GH deficiency: Research demonstrated that hexarelin improved cardiac function (ejection fraction, cardiac output) in hypophysectomized (GH-deficient) rats independently of GH secretion — a finding attributable to direct CD36 signaling in cardiomyocytes.
Macrophage cholesterol efflux: CD36 plays roles in oxidized LDL uptake and foam cell formation in atherosclerosis. Research has examined hexarelin's effects on macrophage lipid metabolism and plaque biology through CD36 modulation.

Tachyphylaxis: A Critical Research Consideration

Hexarelin's most significant research limitation is rapid tachyphylaxis — reduced GH response with repeated administration due to receptor desensitization. Studies in rats showed that after 2-4 weeks of twice-daily hexarelin, the GH response was substantially blunted. This tachyphylaxis occurs faster with hexarelin than with GHRP-2 or ipamorelin, requiring researchers to design protocols accordingly:

Intermittent administration schedules to allow receptor re-sensitization
Combination with GHRH analogs to maintain GH response amplitude despite tachyphylaxis
Short-duration acute studies where sustained responsiveness is not required
Using hexarelin for its CD36-mediated cardiovascular effects (where tachyphylaxis is less relevant) rather than sustained GH stimulation

Comparison with Other GHRPs

vs. Ipamorelin: Ipamorelin is far more selective (no cortisol/prolactin elevation, minimal tachyphylaxis). Hexarelin trades selectivity and sustained responsiveness for greater acute GH pulse amplitude and the unique CD36 cardiovascular research profile.
vs. GHRP-2: GHRP-2 has similar GHSR-1a potency and also elevates cortisol/ACTH, but lacks hexarelin's CD36 binding. GHRP-2 tachyphylaxis is somewhat less pronounced than hexarelin.
vs. GHRP-6: GHRP-6 is the classical reference GHRP, with the most extensive literature base, significant appetite stimulation through peripheral ghrelin-like activity, and lower potency than hexarelin. CD36 activity is not a significant feature of GHRP-6.

Research Applications

Given its unique profile, hexarelin research is best suited to:

Cardiac biology studies where CD36-mediated cardioprotection is the research target
Atherosclerosis and macrophage biology research via CD36 modulation
Acute GH pulse studies requiring maximum pulse amplitude
Comparative GHRP pharmacology studies
Tachyphylaxis mechanism research in the GHSR system

Frequently Asked Questions

Why is hexarelin's CD36 activity considered unique among GHRPs?

CD36 binding was identified as a hexarelin-specific property through studies showing cardiovascular effects in GHSR-1a knockout and GH-deficient models. Most GHRPs do not demonstrate significant CD36 affinity at research concentrations, making hexarelin uniquely valuable for studying CD36-mediated biology in parallel with GHSR-1a effects.

Can hexarelin tachyphylaxis be reversed?

Research has shown that GH responsiveness to hexarelin partially recovers after a period of non-administration (typically 1-2 weeks in rodent studies), consistent with GHSR-1a re-sensitization following receptor downregulation. Combining hexarelin with GHRH analogs can partially overcome tachyphylaxis by providing complementary pituitary stimulation.

How does hexarelin interact with somatostatin?

Like other GHRPs, hexarelin reduces hypothalamic somatostatin tone — the primary mechanism by which GHRPs amplify GH pulse amplitude rather than just triggering release. Combined with GHRH analog administration (which directly stimulates GH synthesis and release), somatostatin suppression by hexarelin produces synergistic GH responses.

References

Locatelli V, et al. (1999). Growth hormone-releasing peptides. European Journal of Endocrinology. PMID: 10087682
Mao Y, et al. (2007). Ghrelin and hexarelin effects on cardiac function. Regulatory Peptides. PMID: 17475348
Bodart V, et al. (2002). CD36 mediates the cardiovascular action of growth hormone-releasing peptides. Circulation Research. PMID: 11834704

Disclaimer: All compounds offered by Palmetto Peptides are strictly for laboratory research and in vitro studies. They are not intended for human consumption, veterinary use, or any therapeutic application. All information provided is for educational and scientific reference only. Palmetto Peptides makes no health claims. Consult a licensed medical professional before handling any research compound.